Founded in 2004, Cenexi, along with its subsidiaries, is engaged primarily in the business of CDMO of pharmaceutical products with expertise in sterile liquid and lyophilized fillfinished drug, including capabilities on oncology and complex products, with revenue for CY21 stood at Euro 184.1 million.
